ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) RecurrenceAccesswire • 10/27/24
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular LensBusiness Wire • 10/14/24
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30Business Wire • 10/09/24
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis RisesAccesswire • 10/08/24
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is LikelySeeking Alpha • 09/19/24
Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?Zacks Investment Research • 09/19/24
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current LevelsSeeking Alpha • 09/19/24
Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investorsCNBC • 09/17/24
Bausch + Lomb's stock soars 18% on report company is considering selling itselfMarket Watch • 09/16/24
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and OlderAccesswire • 09/11/24